Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Abou-Alfa on Sorafenib Plus Doxorubicin in Patients With HCC
January 22nd 2016Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the CALGB 80802 study, which examined sorafenib versus sorafenib plus doxorubicin in patients with advanced hepatocellular carcinoma in the first-line setting.
Dr. Bekaii-Saab on Sequencing Regorafenib and TAS-102 in CRC
January 22nd 2016Tanios Bekaii-Saab, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, discusses sequencing regorafenib and TAS-102 for the treatment of patients with colorectal cancer.
Liposomal Irinotecan OS Advantage Maintained in Updated Pancreatic Cancer Data
Adding liposomal irinotecan to 5-fluorouracil and leucovorin reduced the risk of death by 25% for patients with metastatic pancreatic cancer following progression on a gemcitabine-based regimen.
Holly Prigerson on Chemotherapy Regimens for Patients With Advanced Gastric Cancer
January 21st 2016Holly G. Prigerson, PhD, professor of Sociology in Medicine, Irving Sherwood Wright Professor in Geriatrics, Joan and Sanford I. Weill Department of Medicine, director, Center for Research on End of Life Care, Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses chemotherapy regimens for patients with advanced gastric cancer.
New Neoadjuvant Regimen Shows Similar Efficacy, Less Toxicity in Rectal Cancer
Preoperative treatment with short-course radiation therapy plus 3 cycles of chemotherapy improved overall survival (OS) and was associated with fewer adverse events compared with standard chemoradiation for patients with locally advanced rectal cancer.
Results for Lu-Dotatate in Patients With Midgut NETs Continue to Impress
January 19th 2016For patients with advanced midgut neuroendocrine tumors, the peptide receptor radionuclide therapy Lu-Dotatate continues to confer a major therapeutic benefit, reducing the risk of disease progression or death by 79% and signaling an improvement in overall survival as well.
Nivolumab's Survival Benefit Sustained Across RCC Subgroups
January 11th 2016Nivolumab’s second-line survival benefit in renal cell carcinoma was consistent across subgroups categorized by patient risk status, prior treatment, and degree of metastases, according to an update of the phase III CheckMate-025 trial.
Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer
January 11th 2016Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.
Hypofractionated Radiotherapy May Be New Standard of Care in Prostate Cancer
Hypofractionated radiotherapy demonstrated similar toxicity and was noninferior to standard radiation therapy for preventing PSA increases or disease recurrences for men with intermediate-risk prostate cancer.
Combo of Celecoxib and Zoledronic Acid Improves Survival in Metastatic Prostate Cancer
January 9th 2016Adding celecoxib and zoledronic acid to standard treatment extended survival in men with metastatic prostate cancer commencing first-line hormone therapy, according to updated data from the STAMPEDE trial.
Avelumab Spurs Responses in Refractory Metastatic Urothelial Cancer
The investigational anti-PD-L1 antibody avelumab demonstrated antitumor activity with an acceptable safety profile in a phase Ib trial of patients with metastatic urothelial cancer refractory to standard therapy.
Dr. Kibel on Take-Home Messages in Field of Genitourinary Cancers
January 9th 2016Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.
Dr. Choueiri on Significance of CheckMate-025 Study for RCC
January 8th 2016Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma.
Docetaxel First Choice After Abiraterone in 50% of Patients with mCRPC
A post hoc analysis of the COU-AA-302 clinical trial suggests that docetaxel has antitumor activity as first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer.
Dr. Siefker-Radtke on Advancements in Small Cell Urothelial Cancer
January 8th 2016Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.
Can Aspirin Avert Lethal Prostate Cancer? Long-term Study Suggests a Possible Role
January 4th 2016Aspirin’s benefits may now extend to reducing the risk of deadly prostate cancer, according to the results of an observational study which found that previously undiagnosed men who took regular aspirin had a 24% lower risk of developing a lethal form of the disease.
%201%20(1)%20copy.jpg?fit=crop&auto=format)
